ライフサイエンスコーパス: liver failure

1 is a successful treatment for patients with liver failure.

2 Sepsis rate was also predictive of IFALD and liver failure.

3 a in LR and have implications for therapy of liver failure.

4 divided into hyperacute, acute and subacute liver failure.

5 Ascites is a common complication of subacute liver failure.

6 nonalcoholic steatohepatitis, fibrosis, and liver failure.

7 egenerative therapies for APAP-induced acute liver failure.

8 ry and it is the second most common cause of liver failure.

9 The treatment was not effective in acute liver failure.

10 rrounding normal liver, reducing the risk of liver failure.

11 vival in a lethal model of resection-induced liver failure.

12 hepatic fibrosis, cirrhosis, and eventually liver failure.

13 s with decompensated cirrhosis and fulminant liver failure.

14 Group 3 animals declined rapidly, with acute liver failure.

15 onic, acute-on-chronic, or acute cholestatic liver failure.

16 roliferation after hepatectomy, resulting in liver failure.

17 iculum stress, oxidative stress, and finally liver failure.

18 r decompensations including acute-on-chronic liver failure.

19 that lead to generalized infection and acute liver failure.

20 f neurological complications associated with liver failure.

21 ses residual hepatocyte function, leading to liver failure.

22 peutic option to treat posthepatectomy acute liver failure.

23 on was abandoned because of the high risk of liver failure.

24 and ultimately hepatocellular carcinoma and liver failure.

25 diet before azoxymethane (AOM)-induced acute liver failure.

26 large-scale production for the treatment of liver failure.

27 n lead to herpes simplex virus-induced acute liver failure.

28 g in patients with paracetamol-induced acute liver failure.

29 hy is a serious neurological complication of liver failure.

30 tus are strongly associated with etiology of liver failure.

31 4 changed mental status, and one death from liver failure.

32 n the neurological complications after acute liver failure.

33 isease-acute liver failure (ALF) and chronic liver failure.

34 tributing factor for cerebral edema in acute liver failure.

35 tcomes in acute acetaminophen (APAP)-related liver failure.

36 ophen overdose is the leading cause of acute liver failure.

37 re were no cases of hepatic-related death or liver failure.

38 assessment of patients with acute-on-chronic liver failure.

39 in the IDILI caused by drugs that can cause liver failure.

40 d fibrosis and may progress to cirrhosis and liver failure.

41 n is altered on monocytes from patients with liver failure.

42 is during the transition of NAFL to NASH and liver failure.

43 -4 (TLR4) pathway plays an important role in liver failure.

44 hepatectomy with less risk of post-operative liver failure.

45 n was reduced by recAP in ACLF but not acute liver failure.

46 option for prevention of ACLF but not acute liver failure.

47 ation and/or development of acute-on-chronic liver failure.

48 indicating protection from resection-induced liver failure.

49 sparing, specific and novel therapy in acute liver failure.

50 decompensated cirrhosis or acute-on-chronic liver failure.

51 ulated even in late-stage APAP-induced acute liver failure.

52 f 165 children admitted with pediatric acute liver failure, 136 met the inclusion criteria and 45 of

53 with ALF, 20 patients with acute-on-chronic liver failure, 15 patients with cirrhosis with no eviden

54 uring the postpartum period, and 4 were from liver failure (2 of the women who died from liver failur

55 e significant medical comorbidities, such as liver failure (9.9% vs 4.2%; p < 0.001), metastatic canc

56 In patients with acetaminophen-induced acute liver failure, a low serum level of CSF1 was associated

57 cirrhosis (Non-ACLF) and in acute-on-chronic liver failure (ACLF) by CCT and ROTEM including agreemen

58 Acute-on-chronic liver failure (ACLF) in cirrhosis is an increasingly rec

59 Acute-on-chronic liver failure (ACLF) in cirrhosis is characterized by ac

60 ute decompensation (AD) and acute-on-chronic liver failure (ACLF) in cirrhosis.

61 ors to predict survival and acute-on-chronic liver failure (ACLF) in patients awaiting LT, as well as

62 The development of acute-on-chronic liver failure (ACLF) in patients with liver cirrhosis is

63 decompensated cirrhosis and acute-on-chronic liver failure (ACLF) include susceptibility to infection

64 Acute-on-chronic liver failure (ACLF) is an ailment with high incidence o

65 Acute on chronic liver failure (ACLF) is associated with multisystem orga

66 Acute-on-chronic liver failure (ACLF) is characterized by acute decompens

67 The term acute-on-chronic liver failure (ACLF) is intended to identify patients wi

68 Although acute-on-chronic liver failure (ACLF) is the most severe clinical stage o

69 Acute on chronic liver failure (ACLF) results in extremely high short-ter

70 The acute-on-chronic liver failure (ACLF) syndrome is characterized by acute

71 and prognostic criteria of acute-on-chronic liver failure (ACLF) were developed in patients with no

72 lantation for patients with acute-on-chronic liver failure (ACLF) with 3 or more failing organs (ACLF

73 The presence of acute on chronic liver failure (ACLF) with three or more organs failing (

74 he progression of acute and acute-on-chronic liver failure (ACLF).

75 patients with cirrhosis and acute on chronic liver failure (ACLF).

76 titis B Virus (HBV) related acute-on-chronic liver failure (ACLF).

77 s a lack of data on PICD in acute-on-chronic liver failure (ACLF).

78 titis B infection (CHB) and acute-on-chronic liver failure (ACLF).

79 shed in liver cirrhosis and acute-on-chronic liver failure (ACLF).

80 , with clinical features of acute-on-chronic liver failure (ACLF).

81 d cirrhosis (AD, n = 52) or acute-on-chronic liver failure (ACLF, n = 57).

82 s transplanted with grade-3 acute-on-chronic liver failure (ACLF-3).

83 Patients were comparable in severity of liver failure, active bleeding at endoscopy, and initial

84 llected to measure cytokines and a marker of liver failure (alanine aminotransferase); liver tissues

85 as also analyzed by underlying disease-acute liver failure (ALF) and chronic liver failure.

86 ticenter cohort of adult patients with acute liver failure (ALF) and in an acetaminophen (APAP)-induc

87 Specific efficacious therapies for acute liver failure (ALF) are limited and time-dependent.

88 Twelve percent of all acute liver failure (ALF) cases are of unknown origin, often t

89 BACKGROUND & AIMS: Patients with acute liver failure (ALF) have defects in innate immune respon

90 BACKGROUND DATA: Patients with severe acute liver failure (ALF) have extreme physiologic dysfunction

91 tamol) poisoning is a leading cause of acute liver failure (ALF) in humans and induces hepatocyte nec

92 (HEV) infection is a leading cause of acute liver failure (ALF) in many developing countries, yet ra

93 inophen (APAP) is the leading cause of acute liver failure (ALF) in the United States.

94 Acute liver failure (ALF) induced by diffuse metastatic diseas

95 Acute liver failure (ALF) is a rare syndrome of severe, rapid-

96 Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant morta

97 Pediatric acute liver failure (ALF) is life threatening with genetic, im

98 Acute liver failure (ALF) is uncommon but progresses rapidly w

99 Patients who have acute liver failure (ALF) or require an acute retransplantatio

100 op severe acute liver injury (sALI) or acute liver failure (ALF) remain little known.

101 rity, it represents the major cause of acute liver failure (ALF) requiring liver transplantation in U

102 taminophen (APAP, paracetamol)-induced acute liver failure (ALF) showed significant differences in th

103 infection remains a frequent cause of acute liver failure (ALF) worldwide.

104 nts with acute liver dysfunction (e.g. acute liver failure (ALF), acute-on chronic liver failure (AoC

105 LPS) and concanavalin A (ConA)-induced acute liver failure (ALF), but the mechanism by which FK866 af

106 Acute liver failure (ALF), characterized by sudden onset of co

107 ant centers coordinate complex care in acute liver failure (ALF), for which liver transplant (LT) can

108 disease (CLD) is required to diagnose acute liver failure (ALF).

109 tension and mortality in patients with acute liver failure (ALF).

110 y models in mice, and in patients with acute liver failure (ALF).

111 inophen toxicity is a leading cause of acute liver failure (ALF).

112 rious in pregnancy and could result in acute liver failure (ALF).

113 in a patient with dengue virus induced acute liver failure (ALF).((1)) Their report highlights the ca

114 eveloped hepatocellular carcinoma, and 1 had liver failure, all of whom were in the obese group.

115 The single patient with liver failure also developed multiorgan failure requirin

116 Importantly, 1 patient developed liver failure and 2 patients developed protein-caloric m

117 nderstanding of the processes culminating in liver failure and cancer and to prioritize vaccine candi

118 n people worldwide and is a leading cause of liver failure and cancer.

119 24 patients with acetaminophen-induced acute liver failure and compared with 10 healthy controls.

120 TGFbeta1 signaling during AOM-induced acute liver failure and contributes to both liver pathology an

121 use interruption of chemotherapy and lead to liver failure and death.

122 rug screening and therapeutic strategies for liver failure and diabetes.

123 omising alternative therapeutic approach for liver failure and different cell sources have been teste

124 Mice given SR9009 developed less-severe liver failure and had longer survival times than mice gi

125 this study was to assess TSP-1 during acute liver failure and HE pathogenesis.

126 cted with azoxymethane (AOM) to induce acute liver failure and HE.

127 Severe hepatic insults can lead to acute liver failure and hepatic encephalopathy (HE).

128 ple worldwide and is a major risk factor for liver failure and hepatocellular carcinoma.

129 epatitis B virus (HBV) is a leading cause of liver failure and hepatocellular carcinoma.

130 inophenol [APAP]) is the main cause of acute liver failure and liver transplantation in several Weste

131 attractive method for the treatment of acute liver failure and liver-based metabolic disorders.

132 m survival of patients with acute-on-chronic liver failure and multiple organ failure.

133 cholestatic liver injury, which may lead to liver failure and need for organ transplantation.

134 yperammonemia animal models, including acute liver failure and ornithine transcarbamylase deficiency,

135 us on the current approach to neonatal acute liver failure and the progress made in the diagnosis and

136 ntation (LT) between patients with fulminant liver failure and those with cirrhosis and severe hepati

137 e hemorrhagic fever, neurological disorders, liver failure, and blindness, which could collectively b

138 tment prevented hepatocyte death, subsequent liver failure, and death in the rodent model.

139 haracterised by florid hepatic inflammation, liver failure, and death within 28 days in 35% of patien

140 an lead to severe acute hepatitis, fulminant liver failure, and death.

141 CV develop complications, such as cirrhosis, liver failure, and hepatocellular carcinoma over a perio

142 : Patients with NAFLD may develop cirrhosis, liver failure, and hepatocellular carcinoma.

143 s the risk for the development of cirrhosis, liver failure, and hepatocellular carcinoma.

144 us condition that can progress to cirrhosis, liver failure, and hepatocellular carcinoma.

145 Two individuals died of liver failure, and one individual was successfully treat

146 ical record-confirmed hepatic-related death, liver failure, and other clinically significant hepatic

147 were impaired due to systemic inflammation, liver failure, anticoagulants (heparins, phenprocoumon,

148 acute liver failure (ALF), acute-on chronic liver failure (AoCLF) or decompensated chronic liver dis

149 generalized infections and subsequent acute liver failure are less well understood.

150 Urea cycle defects and acute or chronic liver failure are linked to systemic hyperammonemia and

151 ; RR, 0.35 [95% CI, 0.16-0.75]; P = .006) or liver failure (ARR, 0.046 [95% CI, 0.008-0.088]; RR, 0.2

152 Recognition of acute-on-chronic liver failure as a clinically and pathophysiologically d

153 The EGCG treatment resulted in liver failure as evidenced by extensive hepatocyte necro

154 ficant impairment of liver function or overt liver failure as the cause of death in COVID-19 rarely o

155 tly is considered a consequence of secondary liver failure because of which liver transplantation is

156 9 expression in acetaminophen-induced acute liver failure being mediated both by circulating endogen

157 previously been implicated in cirrhosis and liver failure but not in isolated portal hypertension.

158 The greatest cause of death was liver failure, but attempted anti-hepatitis C virus ther

159 Fatty liver is a preventable cause of liver failure, but early risk factors for adulthood fatt

160 Treatment of acute liver failure by cell transplantation is hindered by a s

161 chronic liver failure grades 1-3 and Chronic Liver Failure-C-Organ Failure liver subscore equals to 3

162 reased kidney, brain, or coagulation Chronic Liver Failure-C-Organ Failure subscores.

163 esic responsible for more than half of acute liver failure cases.

164 We describe a case of acute liver failure caused by echovirus 25 (E25) in a previous

165 first report of acute hepatic necrosis with liver failure caused by Salmonella in a dog.

166 atients can develop hepatitis, coagulopathy, liver failure, central nervous system involvement, multi

167 ng survival, while in patients with advanced liver failure (Child B/C), EVL alone carries an increase

168 Failure dataset with adoption of the Chronic Liver Failure-classification resulted in similar finding

169 ult patients with PCLD to those with chronic liver failure (CLF) and hepatocellular carcinoma.

170 abase on patients with cirrhosis and chronic liver failure (CLF) from 2006 through 2014, and data on

171 ll patients with acetaminophen-induced acute liver failure compared with healthy controls (p < 0.0001

172 A new diagnostic score, the Chronic Liver Failure Consortium (CLIF-C) organ failure score, h

173 of 1-year mortality, independent of Chronic Liver Failure Consortium acute-on-chronic liver failure

174 sociation for the Study of the Liver Chronic Liver Failure Consortium criteria.

175 oimmune hepatitis) or patients without acute liver failure (controls) collected from a DILI Biobank i

176 in 7.6% of cases; 40% of these had nonacute liver failure courses.

177 17 because of ALF defined by Pediatric Acute Liver Failure criteria (raised transaminases, Internatio

178 sociation for the Study of the Liver-chronic liver failure criteria.

179 by applying the recently introduced Chronic Liver Failure-criteria.

180 In a porcine model of severe liver failure, damage was assured in all animals by surg

181 s analysis and combined outcomes of death or liver failure (defined as MELD score >/=30).

182 ve therapy for toxic ingestion or idiopathic liver failure (DT) in a level 1 trauma center and large

183 e, outcomes, and prognostic factors of early liver failure (ELF) after transjugular intrahepatic port

184 bilize the lost metabolic function for acute liver failure, end-stage and congenital liver diseases,

185 plantation can halt life-threating recurrent liver failure episodes and cure type 1 diabetes.

186 r complications of WRS, including repetitive liver failure episodes and poorly controlled diabetes.

187 features observed in patients with subacute liver failure, especially ascites.

188 analysis in individuals with acute infantile liver failure, especially if triggered by fever.

189 ic steatohepatitis can lead to cirrhosis and liver failure for which there are currently no approved

190 Liver failure from any number of sources (e.g. viral inf

191 f existing liver disease distinguishes acute liver failure from decompensated cirrhosis or acute-on-c

192 ing the progression of non-alcoholic chronic liver failure from fatty liver disease to steatohepatiti

193 compensated cirrhosis and moderate-to-severe liver failure from nine university hospitals in six Euro

194 ith multiple organ failure (acute-on-chronic liver failure grade 2-3).

195 First, 101 patients with acute-on-chronic liver failure grades 1-3 and Chronic Liver Failure-C-Org

196 liver failure (2 of the women who died from liver failure had received isoniazid [1 in each group]).

197 d severe laboratory abnormalities, and acute liver failure has been reported (Table ).

198 Because of its rarity, acute liver failure has not been studied in large, randomised

199 Although animal models of acute liver failure have been established, the study of the pa

200 long-term risk for progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-relat

201 ion is a global health problem, resulting in liver failure, hepatocellular carcinoma, and liver-relat

202 ients who have been transplanted for chronic liver failure; however long-term survival is higher comp

203 been shown to contribute to HE during acute liver failure; however, TGFbeta1 must be activated to bi

204 er fibrosis leads to portal hypertension and liver failure; however, the mechanisms leading to fibros

205 , 0.21; 95% CI, 0.06-0.74), acute-on-chronic liver failure (HR, 0.29; 95% CI, 0.03-0.99), and a model

206 Cl4-treated rats; and rapidly reversed fatal liver failure in CCl4-treated animals by restoring disea

207 constitutes a safe and efficient therapy for liver failure in children.

208 cirrhosis in the EASL-CLIF Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC) study.

209 o presented with recurrent episodes of acute liver failure in early infancy and are affected by cereb

210 ndoPC-derived hepatocytes are able to rescue liver failure in Fah(-/-)Rag2(-/-) mice after transplant

211 nage of acid-base homeostasis, diabetes, and liver failure in point-of-care settings.

212 th fibrosis and steatosis, leading in one to liver failure in the course of infections.

213 for the management acute or acute on chronic liver failure in the ICU, acknowledging that most recomm

214 on the management acute or acute on chronic liver failure in the ICU, related to five groups (cardio

215 liver injury (DILI) is the leading cause of liver failure in the United States and the most common c

216 e leading causes of hepatotoxicity and acute liver failure in the United States.

217 taminophen (APAP) is the main cause of acute liver failure in the West.

218 ) overdose is the most common cause of acute liver failure in the Western world, with limited treatme

219 inophen (APAP) is the leading cause of acute liver failure in the Western world.

220 injury and the most frequent cause of acute liver failure in the Western world.

221 model of resistance to Fas receptor-mediated liver failure in the wild-derived MSM strain, compared w

222 curred (2.7%): hemothorax in one patient and liver failure in two, with major portal-systemic shunts.

223 Causes of acute liver failure include paracetamol toxicity, hepatic isch

224 ss that occurs after liver injury, but acute liver failure is a complex and fatal disease which is di

225 Acute liver failure is a rare and severe consequence of abrupt

226 iovascular diseases in patients with chronic liver failure is associated with increased morbidity and

227 Acute-on-chronic liver failure is associated with numerous consecutive or

228 Acute liver failure is divided into hyperacute, acute and suba

229 l research, cell transplantation therapy for liver failure is impeded by a shortage of human primary

230 ibility to development of ACLF whereas acute liver failure is likely due to direct hepatoxicity.

231 completion of stage 2: >=96%, postoperative liver failure (ISGLS-criteria) after stage 2: <=5%, ICU

232 Liver failure leads to the massive necrosis of hepatocyt

233 atients with WD who have progressed to acute liver failure, leaving liver transplantation as the only

234 Liver failure (LF) is associated with prolonged hospital

235 liver damage and possibly the development of liver failure mainly by activating Kupffer cells.

236 Patients with paracetamol-induced acute liver failure managed at intensive care units in the UK

237 We employed two mouse liver damage and liver failure models induced by lipopolysaccharide (LPS)

238 tions classified as grade III or higher were liver failures occurring in patients with Child-Pugh cla

239 rtment syndrome must be suspected when acute liver failure occurs in patients with subcapsular hemato

240 Liver failure of unknown etiology (LFUE) has a transplan

241 was increased in acetaminophen-induced acute liver failure on day 1 compared with healthy controls (p

242 failure, whether arising directly from acute liver failure or from decompensated chronic liver diseas

243 rity from hepatic inflammation to cirrhosis, liver failure or hepatocellular carcinoma (HCC).

244 No patient with reactivation experienced liver failure or liver-related death within 36 weeks aft

245 t none in the RASPE group, had postoperative liver failure (P = 0.012).

246 Pediatric acute liver failure (PALF) is a potentially devastating condit

247 o) is predominant in the NIH Pediatric Acute Liver Failure (PALF) Study.

248 nuous renal replacement therapy use in acute liver failure patients and to assess its impact on hyper

249 Retrospective analysis of acute-on-chronic liver failure patients receiving either standard medical

250 approach to hyperammonemia control in acute liver failure patients.

251 with reduced ammonia concentrations in acute liver failure patients.

252 association with ascites and posthepatectomy liver failure (PHLF) after major hepatectomy.

253 the influence of acetaminophen-induced acute liver failure plasma and endogenous DNA on Toll-like rec

254 e incubated with acetaminophen-induced acute liver failure plasma with and without deoxyribonuclease-

255 stimulation with acetaminophen-induced acute liver failure plasma, which was abrogated by preincubati

256 In drug-induced acute liver failure, plasma levels correlate with outcome.

257 the critical period for survival after acute liver failure, providing promising clues of integration

258 of renal replacement therapy-especially when liver failure reduces lactate elimination.

259 The mechanisms that drive irreversible acute liver failure remain poorly characterized.

260 extensive liver resection, post-hepatectomy liver failure remains one of the most lethal complicatio

261 r detrimental in acetaminophen-induced acute liver failure remains unknown.

262 transplantation in paracetamol-induced acute liver failure require re-evaluation.

263 b again, and her cancer-related symptoms and liver failure resolved.

264 e adverse reaction, developing posttreatment liver failure resulting in death.

265 represents the most frequent cause of acute liver failure, resulting in death or liver transplantati

266 ic Liver Failure Consortium acute-on-chronic liver failure score (CLIF-C ACLFs).

267 evels were measured on admission and Chronic Liver Failure-Sequential Organ Failure Assessment criter

268 tion of hiPSC-EB-HLC in a rat model of acute liver failure significantly prolonged the mean survival

269 n, used in nearly 30% of patients with acute liver failure, still provides a life-saving alternative

270 ar prognostic power as the established Acute Liver Failure Study Group index (C-statistic 0.87 vs. 0.

271 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686

272 t assay with clinical data from the US Acute Liver Failure Study Group registry (1998-2014).

273 les of 681 adults enrolled in the U.S. Acute Liver Failure Study Group were tested for anti-HEV immun

274 The U.S. Acute Liver Failure Study Group, comprised of 33 tertiary care

275 hepatitis (AH) is a syndrome of jaundice and liver failure that occurs in a minority of heavy consume

276 lines to a Fah(-/-) Il2rg(-/-) rat model of liver failure, the rat liver stem cells engrafted into t

277 nd death associated with tyrosinemia-induced liver failure, they developed regenerating nodules simil

278 er is a central regulator of metabolism, and liver failure thus constitutes a major health burden.

279 or patients with acetaminophen-induced acute liver failure to develop sepsis, which may culminate in

280 t of patients with paracetamol-induced acute liver failure to identify those needing emergency liver

281 critically ill children with pediatric acute liver failure to provide stability and bridge to transpl

282 um ACLF score (CLIF-C ACLFs) and presence of liver failure (total bilirubin >/=12 mg/dL) at ACLF diag

283 serious liver-related adverse events such as liver failure, variceal bleeding, serious infections, sp

284 The risks of death and progression to liver failure varied greatly by fibrosis stage.

285 Acute liver failure was induced with Galactosamine-LPS and in

286 Posthepatectomy liver failure was rare, and no difference was observed (

287 renal replacement therapy in pediatric acute liver failure were changed in 2011 following preliminary

288 Patients with acute liver failure were excluded from the analysis.

289 Usual causes of acute liver failure were excluded, all drugs were stopped and

290 atients with acute hepatitis B (AHB) without liver failure were included.

291 Children with pediatric acute liver failure were managed according to a set protocol.

292 ifiable factor associated with mortality and liver failure, whereas enteral autonomy correlates with

293 Liver failure, whether arising directly from acute liver

294 Among children with pediatric acute liver failure who did not receive a liver transplant, us

295 report a case of an adult male with EPP and liver failure who successfully underwent a sequential li

296 d, the study of the pathogenesis of subacute liver failure with ascites complication is hampered by t

297 aimed at providing a mouse model of subacute liver failure with ascites complication.

298 r investigating the pathogenesis of subacute liver failure with ascites complication.

299 injury (DILI) is an important cause of acute liver failure, with limited therapeutic options.

300 Unfortunately, liver failure worsened dramatically while patient develo